Home › NDC Lookup › RxCUI directory › RxCUI 904425

Alendronic acid 5 MG Oral Tablet — RxCUI 904425

Name: Alendronic acid 5 MG Oral Tablet (RxCUI 904425)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 904425 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI904425

Official nameAlendronic acid 5 MG Oral Tablet

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known asalendronic acid 5 MG (as alendronate sodium 6.53 MG) Oral Tablet; alendronate sodium 5 MG Oral Tablet

FDA products mapped5

Package NDCs mapped9

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Alendronate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Unfortunately, going back to bed after taking it is one of the biggest things to avoid. Alendronate can irritate the lining of your esophagus — the tube that connects your mouth to...
Why do I have to stay sitting or standing for 30 minutes after taking alendronate? Can't I just go back to bed?
It matters a lot — studies have shown that taking alendronate with coffee or orange juice reduces how much of the medication your body absorbs by about 60%. That means the drug may...
Why does it matter so much that I take it with plain water? What happens if I use coffee or juice?

📖 Read our full Alendronate guide →

🕸️ Concept Web — How Alendronic acid 5 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Alendronic acid 5 MG Oral Tablet RxCUI 904425 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Alendronate 46041 IN
- Alendronic acid 236083 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Fosamax 114265 BN
Dose forms 13

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Alendronate Oral Tablet 904395 SCDF
- Alendronic acid Oral Tablet 2645532 SCDFP
- Alendronate Oral Product 1367010 SCDG
- Alendronate Pill 1367009 SCDG
- Alendronic acid Oral Product 2662744 SCDGP
- Alendronic acid Pill 2662977 SCDGP
- Alendronate Oral Tablet [Fosamax] 904398 SBDF
- Alendronic acid Oral Tablet [Fosamax] 2654989 SBDFP
- +5 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Alendronic acid 5 MG 904424 SCDC
- Alendronic acid 5 MG Oral Tablet [Fosamax] 904427 SBD
- Alendronic acid 5 MG [Fosamax] 904426 SBDC

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Alendronic acid 5 MG SCDC · 904424
Alendronate Oral Tablet SCDF · 904395
Alendronic acid Oral Tablet SCDFP · 2645532
Alendronate Oral Product SCDG · 1367010
Alendronate Pill SCDG · 1367009
Alendronic acid Oral Product SCDGP · 2662744
Alendronic acid Pill SCDGP · 2662977

Brand-Name Concepts

Alendronic acid 5 MG Oral Tablet [Fosamax] SBD · 904427
Alendronic acid 5 MG [Fosamax] SBDC · 904426
Alendronate Oral Tablet [Fosamax] SBDF · 904398
Alendronic acid Oral Tablet [Fosamax] SBDFP · 2654989
Fosamax Oral Product SBDG · 1173285
Fosamax Pill SBDG · 1173286
Fosamax BN · 114265

📦 FDA Products & Package NDCs

5 products · 9 package NDCs

9 package NDCs map to RxCUI 904425 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00115-1676-01	100 TABLET in 1 BOTTLE (0115-1676-01)	Alendronate Sodium	Amneal Pharmaceuticals of New York LLC	2008-02-06
00115-1676-08	30 TABLET in 1 BOTTLE (0115-1676-08)	Alendronate Sodium	Amneal Pharmaceuticals of New York LLC	2008-02-06
00115-1678-01	100 TABLET in 1 BOTTLE (0115-1678-01)	Alendronate Sodium	Amneal Pharmaceuticals of New York LLC	2008-02-06
00115-1678-08	30 TABLET in 1 BOTTLE (0115-1678-08)	Alendronate Sodium	Amneal Pharmaceuticals of New York LLC	2008-02-06
00115-1679-26	12 BLISTER PACK in 1 CARTON (0115-1679-26) / 1 TABLET in 1...	Alendronate Sodium	Amneal Pharmaceuticals of New York LLC	2008-02-06
00115-1679-34	4 BLISTER PACK in 1 CARTON (0115-1679-34) / 1 TABLET in 1 B...	Alendronate Sodium	Amneal Pharmaceuticals of New York LLC	2008-02-06
00115-1680-08	30 TABLET in 1 BOTTLE (0115-1680-08)	Alendronate Sodium	Amneal Pharmaceuticals of New York LLC	2008-02-06
00115-1681-26	12 BLISTER PACK in 1 CARTON (0115-1681-26) / 1 TABLET in 1...	Alendronate Sodium	Amneal Pharmaceuticals of New York LLC	2008-02-06
00115-1681-34	4 BLISTER PACK in 1 CARTON (0115-1681-34) / 1 TABLET in 1 B...	Alendronate Sodium	Amneal Pharmaceuticals of New York LLC	2008-02-06

Observed labelers: Amneal Pharmaceuticals of New York LLC (9) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.